Morphosys shares suffered another big loss today. On Friday afternoon, the biotech stock fell nearly 15 percent to 12, 35 euros, the low of the day was as much as 11.81 euros. With the technical picture of Morphosys shares (WKN: 663200, ISIN: DE0006632003, Chart) already weak, the analyst’s voice is triggering a sell wave today, reinforced by new technical sell signals. The potential support of 13.90/1 .20 euros is clearly diminished, which brings more negative impulses to the share of biotechnology. , The analyst’s negative vote comes from Goldman Sachs in the United States. Its analysts downgraded Morphosys shares from “neutral” to “sell”. At the same time, the target price of the TecDAX stock is significantly lowered from 2 euros to 12 euros. Goldman Sachs attributed the two declines to, among other things, the financial problems of Morphosys. Coupled with the lack of positive catalysts, there is no room for sentiment in the biotech stock market. Cancer drug Monjuvi briefly held the title, but the cancer drug has failed to meet expectations since its release in 2020. Mojnuvi was the backdrop for several operations in the Morphosys forecast. In addition, critics say, Morphosys’ drug pipeline appears thin.